Scinai Immunotherapeutics Enhances Manufacturing with Robotic Aseptic Technology Funding from Israel Innovation Authority

Robotic Aseptic Technology to Revolutionize Scinai Immunotherapeutics’ Manufacturing Capabilities

Scinai Immunotherapeutics Ltd. announces significant strides in its manufacturing capabilities by securing expanded support from the Israel Innovation Authority (IIA) for its robotic aseptic fill and finish platform project. The initiative receives a substantial grant totaling NIS 5 million over a span of two years, with around 66% designated as non-dilutive funding. This financial backing facilitates the acquisition and validation of a state-of-the-art automated robotic-arm aseptic system that adheres to the European Union Good Manufacturing Practice (EU GMP) Annex 1 standards. Scinai aims for completion of this advanced system by the third quarter of 2026, signifying a pivotal development in enhancing the company’s operational efficiency and production standards.

This robotic platform stands to modernize Scinai’s Contract Development and Manufacturing Organization (CDMO) capabilities, particularly in light of its recent acquisition of Recipharm Israel Ltd. The strategic collaboration with Recipharm establishes a dual-site development and manufacturing network, enabling seamless transitions for clients as they move from early clinical developments to full-scale commercial production. By minimizing human intervention, the new robotic system is poised to improve reproducibility, increase productivity, and strengthen contamination control at Scinai’s Jerusalem facility—critical factors as the company endeavors to support complex biologics programs more effectively.

Amir Reichman, Scinai’s CEO, underscores the importance of maintaining disciplined capital allocation while pushing for innovation in sterile manufacturing. Expenditures toward the robotic platform reflect the company’s commitment to meet the rising demands of the biologics sector and enhance patient safety through improved manufacturing practices. Complementing this initiative, Scinai is also closely monitoring the potential launch of a new IIA program that seeks to augment industrial CAPEX investments. This proactive stance indicates Scinai's ongoing strategy to expand its operational footprint within the competitive biotech landscape.

In addition to the advancements in robotic aseptic technology, Scinai’s focused investment strategy highlights its ambition to lead in sterile manufacturing. The integration of cutting-edge technologies not only elevates the company’s production capabilities but also resonates with clients seeking reliable and scalable manufacturing solutions. Scinai’s efforts to innovate align with broader trends within the biotech industry where automation and efficiency remain paramount for success.

As Scinai Immunotherapeutics enhances its operational framework, the bolstered manufacturing capabilities serve not just to improve internal processes, but also to better serve its clientele in the evolving landscape of biologic drug development. This transformative phase marks a significant step toward solidifying Scinai's role in the global biotech market.